Drug Information

Drug General Information
Drug ID
D0S7EH
Former ID
DNCL001656
Drug Name
Fezakinumabx
Synonyms
Sirukumab
Drug Type
Antibody
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 3 [525300]
Company
Pfizer New York, NY
Target and Pathway
Target(s) Interleukin-6 receptor Target Info [543592]
KEGG Pathway Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Non-alcoholic fatty liver disease (NAFLD)
Reactome MAPK3 (ERK1) activation
MAPK1 (ERK2) activation
WikiPathways SIDS Susceptibility Pathways
Senescence and Autophagy in Cancer
IL-6 signaling pathway
Differentiation Pathway
Interleukin-6 signaling
References
Ref 525300ClinicalTrials.gov (NCT02531633) Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis.
Ref 543592(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.